Vorinostat Terminated Phase 1 Trials for Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Splenic Marginal Zone Lymphoma / Post-Transplant Lymphoproliferative Disorder / Recurrent Grade 3 Follicular Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Waldenström's Macroglobulinemia (WM) / Recurrent Adult Burkitt Lymphoma / Hepatosplenic T-Cell Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Grade 1 Follicular Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Recurrent Grade 2 Follicular Lymphoma / Testicular Lymphoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01116154Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma